Carlyle U. S. Healthcare Fund
GPTKB entity
Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fund
|
| gptkbp:currency |
gptkb:USD
|
| gptkbp:economic_sector |
gptkb:United_States
|
| gptkbp:established_in |
gptkb:2013
|
| gptkbp:focuses_on |
Healthcare Investments
|
| gptkbp:funding |
$1 billion
|
| gptkbp:has_exit |
gptkb:coins
Mergers and Acquisitions Secondary Sales |
| gptkbp:headquartered_in |
gptkb:Washington,_D._C.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carlyle U. S. Healthcare Fund
|
| gptkbp:investment |
5-7 years
Growth Stage Financial Analysts Experienced Professionals Generate High Returns Healthcare Experts |
| gptkbp:investment_strategy |
gptkb:health_services
gptkb:Telehealth_Services Personalized Medicine Private Equity Above Average Returns |
| gptkbp:is_debated_in |
gptkb:market_research
Financial Assessment Thorough Analysis |
| gptkbp:is_funded_by |
Fundraising
Investment Period Harvesting Period Distribution Period |
| gptkbp:managed_by |
gptkb:The_Carlyle_Group
|
| gptkbp:partnership |
Institutional Investors
Endowments Pension Funds |
| gptkbp:partnerships |
Research Institutions
Universities Healthcare Organizations |
| gptkbp:performance |
IRR
Cash-on-Cash Returns Multiple on Invested Capital |
| gptkbp:portfolio_company |
Biotechnology Firms
Medical Device Manufacturers Healthcare IT Companies Life Sciences Companies |
| gptkbp:regulatory_compliance |
SEC Regulations
|
| gptkbp:sustainability |
Social Impact
Responsible Investing Environmental Considerations |
| gptkbp:target_market |
gptkb:health_services
gptkb:medical_devices Pharmaceuticals |
| gptkbp:bfsParent |
gptkb:Carlyle_Group
|
| gptkbp:bfsLayer |
5
|